Benzinga | Apr 5, 2021 08:02AM EDT

Exelixis Announces US FDA Accepts Investigational New Drug Application For XB002 In Patients With Advanced Solid Tumors; Says Phase 1 Clinical Trial Expected To Begin In Q2 2021

Exelixis, Inc. (NASDAQ:EXEL) today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug Application (IND) to evaluate the safety, tolerability, pharmacokinetics and preliminary antitumor activity of XB002 in patients with advanced solid tumors. As a next-generation tissue factor-targeting antibody-drug conjugate (ADC), XB002 has the potential for an improved therapeutic index and may provide a favorable safety profile compared with earlier-generation tissue factor-targeting ADCs.